RACGP Red Book Screening Guidelines Flashcards

1
Q

What age range should opportunistic STI screening be performed?

A

15 - 29 year olds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Who are high risk STI populations and how often should they be screened?

A

High risk: aboriginal or TSI, IVDU, sex workers, MSM

Screening: annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How often should absolute CVD risk be assessed?

A
  • every 2 years from age 45

- unless aboriginal or TSI, need to screen every 2 years from age 35

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What components are required to calculate absolute CVD risk? (8)

A

Age, sex, smoking status, total and HDL cholesterol, SBP, diabetes and LVH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cholesterol aims for primary prevention of CVD

A
Total cholesterol < 4
HDL > 1
LDL < 2
Non-HDL < 2.5
TG < 2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How often should cholesterol be assessed/screened?

A

Screening every 5 years from 45 or 35 if aboriginal ort TSI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cholesterol screening in low, moderate and high risk CVD groups

A

Low risk: screen every 5 years
Moderate risk: Consider pharmacotherapy if not reaching targets in 6 months or if family history of premature CVD
High risk: commence rx + antihypertensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is AUSDRISK?

A

Screening tool for risk of developing diabetes, should be done every 3 years in patients over 40 or aboriginal or TSI patients > 18.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How often should HbA1c screening be performed in patients with impaired glucose tolerance?

A

Annually with a fasting glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which patients fall into the high risk for diabetes category and how often should HbA1c be performed?

A

High risk: age > 40 and BMI > 25, AUSDRISK score >12

Screening: either fasting glucose/HbA1c every 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Fasting glucose interpretation

A

< 5.5mmol/L = diabetes unlikely
5.5 – 6.9mmol/L = perform OGTT
> 7mmol/L (or >11.1 non-fasting) = diabetes likely, repeat on separate date to confirm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Risk factors for kidney disease (9)

A
Smoking, 
BMI > 30, 
diabetes, 
HTN, 
Aboriginal or TSI over 30 years old, 
PVD, 
CVD
>60yo 
Hx of AKI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the screening for patients at risk of kidney diease

A

Patients should be screened every 1-2 years with blood pressure check and urine ACR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Interpreting urinary ACR results

A

Normal: < 3.5mg/mmol in women, < 2.5mg/mmol in men
Microalbuminuria: 3.5-35mg/mmol in women, 2.5-25mg/mmol in men
Macroalbuminuria: > 35mg/mmol in women, > 25mg/mmol in men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the rationale behind screening for prostate cancer in men (as per Redbook).

A

No obligation to screen asymptomatic men for PSA
Benefit vs risks
- Risk of over diagnosis & rx, impotence + incontinence
DRE is no longer recommended as it is insufficiently sensitive to detect prostate cancers early enough

High risk: Men with one or more first-degree relatives diagnosed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the categories of risk with colorectal cancer. (Cat 1/2/3)

A

Cat 1: average risk

  • Asymptomatic people with no family history
  • Fhx of a 1st or 2nd degree relative with CRC > age 55

Cat 2: moderate risk

  • Asymptomatic patients with FHx of CRC < age 55
  • 2 x first degree or 1 x first degree + 1 x second degree relative on same side of family with CRC diagnosed at any age

Cat 3: high risk
- Suspicion or confirmed familial polyposis syndrome
(3x 1st or 2nd degree relatives on the same side)
(2x 1st or 2nd degree relatives on the same side with high risk features)
(1x 1st or 2nd degree relative with FAP or microdeletion tumours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the screening for CRC in category 1, 2 and 3 patients.

A

Cat 1 (average risk)

  • FOBT screening every 2 years from > 50 until age 75
  • Actively consider aspirin 100-300mg/day prophylaxis

Cat 2 (moderate risk)

  • iFOBT every 2 years from 40-49
  • Colonoscopy every 5 years from 50 to 74yo
  • Actively consider aspirin 100-300mg/day prophylaxis

Cat 3 (high risk)

  • iFOBT every 2 years from 35-44yo
  • colonoscopy from 45-74yo
  • Refer for genetic screening
  • Refer to bowel cancer specialist
  • Suggest aspirin 100-300mg/day prophylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Follow up after polypectomy: small hyperplastic polyps

A

Nil

19
Q

Follow up after polypectomy: 1-2 small tubular adenomas (<10mm)

A

Colonoscopy in 5 years

20
Q

Follow up after polypectomy: High risk adenomas

A

High risk: three or more, > 10mm, tubulovillous or villous histology or high grade dysplasia
Colonoscopy every 3 years

21
Q

Follow up after polypectomy: Sessile adenomas removed in piecemeal

A

Repeat colonoscopy in 3-6 months and again at 12 months

22
Q

Follow up after polypectomy: > 5 adenomas or > 10 adenomas

A

> 5: Repeat colonoscopy in 12 months

>10: Within 12 months to ensure nil missed

23
Q

Follow up of polyps in patients > 75

A

Nil surveillance, lead time from progression from adenoma to cancer is around 10-20 years

24
Q

Describe breast screening in low risk asymptomatic patients.

A
  • Screening mammogram every 2 years for women aged 50-74

Side note: for every 2000 women invited for screening over 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily

25
Q

Define the risk factors for breast cancer (5).

A

Increasing age, personal history of breast ca/atypical hyperplasia/carcinoma in situ, strong family history, mutation of BRCA, previous radiotherapy

26
Q

Define recommendations for breast screening in patients with a first degree relative, <50yo with breast cancer.

A

Cancer Australia recommends considering annual mammograms from age 40 if women have had a 1st degree relative <50 diagnosed with breast cancer.

27
Q

Which patients are at “moderately” increased risk of breast cancer?

A
  • one first degree relative <50 years of age in absence of high risk features
  • two first degree relatives on same side of family
  • two second degree relatives on same side with at least one <50
28
Q

Define the recommended screening for patients at moderate risk of breast cancer.

A

At least every 2 years from 50-74. May consider annual mammograms from 40 if 1st degree relative <50 with breast cancer.

29
Q

What makes a patient “high risk” for breast cancer? (3)

A

1.Two first degree or second degree relatives on same side diagnosed with breast or ovarian cancer with:
> additaion relatives with breast/ovarian cancer
> breast ca diagnosed before 40
> bilateral breast cancer
> Ashkenazi Jewish ancestry
> breast cancer in male relatives

  1. 1 first degree or second degree relative diagnosed <45 with another first or second degree on same side with sarcoma <45
  2. Known family history of high risk breast cancer gene mutation
30
Q

Risk factors for melanoma.

A

Age + sex, history of any skin ca, number of naevi, FHx, skin and hair pigment, response to sun exposure, evidence of actinic skin damage

31
Q

Define screening for melanoma.

A

Low risk: opportunistic
Increase risk: opportunistic
High risk: self examinations every 3 months and formal skin check every 6 months

32
Q

What is the current screening recommendation for cervical cancer?

A

HPV testing every 5 years from 25-74

33
Q

Are bimanual examinations recommended as part of cervical and ovarian cancer screening?

A

No!

34
Q

Is screening for ovarian cancer recommended?

A

Screening in asymptomatic low risk women is NOT recommended.

35
Q

Is screening for testicular cancer recommended?

A

No - insufficient evidence for routine examination/ screening. Patients who do self-examine have not found to have better survival outcomes or earlier detection.

36
Q

Define the recommendations for glaucoma screening.

A

Increased or high risk: refer for ocular examination, frequency determined by findings of examination.

37
Q

Risk factors for glaucoma.

A

Increased risk: family history, caucasian/asian patients >50, patients of african descent >40

Higher risk: patients > 50 with diabetes, myopia, steroid use, migraines, abnormal BP, history of eye trauma

38
Q

Describe screening for osteoporosis.

A

Average risk: assess risk factors every 12 months

Increased risk: send for DXA

High risk: DXA, repeated no more than every 2 years

39
Q

Define risk factors for osteoporosis. (average, increased and high risk groups)

A

Average risk: women >45, men >50

Increased risk: women >60 with Fhx, smokers, high ETOH, vit D deficiency, low BMI, recurrent falls, sedentary or immobile. Patients with medical conditions which pre-dispose to secondary OP.

High risk: patients >45 with low trauma #s, post menopausal women and older men with vertebral fractures.

40
Q

List the common medical conditions which may predispose patients to secondary osteoporisis.

A

Any endocrine disorder, premature menopause, anorexia, inflammatory conditions (i.e. RA), CKD, liver disease, multiple myeloma, chronic steroid use, diabetes, HIV

41
Q

Prevention of osteoporosis.

A
  1. Lifestyle factors: quit smoking, reduce ETOH
  2. Calcium intake
  3. Fall reduction
  4. Regular weight baring and resistance exercise
  5. Appropriate sun exposure
42
Q

What is the recommended calcium intake to prevent osteoporosis?

A

1000mg calcium intake for men until 70 and women until 50

1300mg for women >50 to prevent bone loss.

43
Q

Screening tests not recommended in low risk GP populations.

A
MTHFR
Homocysteine
Ca125/transvaginal US
TFTs
Vitamin D
Bimanual pelvic exam